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Purpose. To analyse current clinicopathological enucleation indications in a large third-referral centre in a developed country
(Hungary) over a period of 12 years. Methods. Retrospective review was performed on 547 enucleated eyes of 543 patients (48.6%
males, age 52.7± 24.5 years) who were operated on between 2006 and 2017 at the Department of Ophthalmology of Semmelweis
University, in Budapest, Hungary. For each subject, clinicopathological data, including patient demographics, indications for
enucleation, B-scan ultrasound reports, operative details, and histopathological analyses, were reviewed. Primary enucleation in-
dications were classified into trauma, tumours, systemic diseases, surgical diseases, infections or inflammations, miscellaneous
diseases, and unclassifiable groups. Clinical immediate enucleation indications were classified as tumours, atrophia or phthisis bulbi,
infection or inflammation, painful blind eye due to glaucoma, acute trauma, threatening or spontaneous perforation, cosmetic causes,
and expulsive bleeding. Results. *e most common primary enucleation indications were tumours (47.3%), trauma (16.8%), surgical
diseases (15.7%), infection or inflammation (11.6%), systemic diseases (5.1%), miscellaneous diseases (2.0%), and unclassifiable
diseases (1.5%). Clinical immediate enucleation indications were tumours (46.1%), atrophia or phthisis bulbi (18.5%), infection or
inflammation (18.5%), painful blind eye due to glaucoma (11.2%), acute trauma (3.7%), threatening or spontaneous perforation
(1.3%), cosmetic reasons (0.5%), and expulsive bleeding (0.4%). Conclusions. Intraocular tumours represent the most common
clinicopathological indication for ocular enucleation in our study population. Following ocular trauma and systemic diseases, the rate
of enucleation decreased in the last decade, compared to those previously reported in other developed countries. However, changes
were not observed for surgical diseases, infectious and inflammatory causes, or for miscellaneous and unclassified diseases. Orbital
implant financing should be increased to ensure better postoperative aesthetic rehabilitation, following enucleation in Hungary.
1. Introduction
Enucleation is the removal of the entire globe and a section of
the optic nerve. It is sometimes an unavoidable end-stage
solution for several ophthalmic diseases. *is procedure may
be required after severe ocular trauma, tumours, infections, or
painful blind eye [1]. Indications for enucleation—since the
first description of the surgery in 1583 by Bartisch—may
differ over time, with changing incidences of different
ophthalmic conditions (e.g., diabetes mellitus, secondary
glaucoma, and tumours) and therapeutic regimens
(e.g., panretinal photocoagulation, intravitreal injections, and
chemotherapies) [2].
*ere have been several clinicopathological studies on
indications for enucleation, but these surveys are not current
or were published in developing countries [3–7]. *e order
of primary clinical enucleation indications varies among
different countries.
Hindawi
Journal of Ophthalmology
Volume 2019, Article ID 2042459, 7 pages
https://doi.org/10.1155/2019/2042459
Since there is almost no up-to-date information about
enucleation in European countries, the primary aim of this
study was to analyse current enucleation indications in a
developed country (Hungary) over a period of 12 years.
2. Materials and Methods
*is retrospective study was undertaken at a tertiary eye care
centre, to analyse the current indications for enucleation in
Hungary. *e study was performed in accordance with the
Declaration of Helsinki Guidelines for Human Research.
*is retrospective review was conducted on 547 eyes
of 543 patients who underwent enucleation at the De-
partment of Ophthalmology of Semmelweis University,
between January 2006 and December 2017. For each subject,
clinicopathological data were reviewed, which included
patient demographics, indications for enucleation, B-scan
ultrasound reports, operative details, and histopathological
analyses. Final diagnosis was based on clinical history and
histopathological findings. Paraffin sections stained with
haematoxylin-eosin and histopathological charts were
available for 535 (97.8%) globes.
Primary enucleation indications (classification of de
Gottrau et al. [3]; based on clinical history and histological
reports) were divided into seven groups: trauma, tumours
(intraocular, periocular, or intraorbital), systemic diseases,
surgical diseases (treated or untreated), infectious and in-
flammatory diseases, miscellaneous diseases, and unclassifi-
able diseases due to incomplete case history. Second,
immediate clinical enucleation indications were categorised
using the classification of de Gottrau et al. [3], modified with
three additional diagnosis groups, such as threatening or
spontaneous perforation, expulsive bleeding, and cosmetic
reasons. *erefore, the immediate clinical enucleation in-
dications were (last diagnosis before anophthalmia surgery)
tumour, atrophia or phthisis bulbi, infection or inflammation,
painful blind eye due to glaucoma, acute trauma (within the
first month after trauma because of unrepairable blind eye
and fear of sympathetic ophthalmia), threatening or spon-
taneous perforation, cosmetic causes, and expulsive bleeding.
Statistical analysis was performed with Statistica 8.0
(StatSoft Inc., Tulsa, OK, USA). Data were expressed as
median with standard deviation (SD). *e chi-squared test
was used to evaluate differences among groups. A p value
lower than 0.05 was considered statistically significant.
3. Results
*ere were 266 (48.6%) males and 281 (51.4%) females in the
study population. *e patient age was 52.7± 24.5 years
(range, 3months to 100 years).
Age at the time of enucleation was as follows: for
traumas, 48.6± 20.9 years (range, 3–100 years) (n� 92); for
tumours, 51.2± 25.7 years (range, 0.3–87 years) (n� 259);
for systemic diseases, 55.4± 23.4 years (range 1–81 years)
(n� 28); for surgical diseases, 50.1± 27.2 years (range
0.25–94 years) (n� 86); for infectious or inflammatory dis-
eases, 64.7± 18.9 years (range 15–93 years) (n� 63); for the
miscellaneous group, 29.5± 18.2 years (range 5–64 years)
(n� 11); and for the not-classified group, 58.3± 27.2 years
(range 6–84 years) (n� 8). Within the tumour group, the
age of patients at the time of surgery was significantly
lower among retinoblastoma (RB) patients, 1.9± 1.5 years
(range 0.3–8 years) (n� 36), than among those with uveal
melanoma, 61.6± 13.9 years (range 18–87 years) (n� 200)
(p< 0.0001).
*e age distribution of the subjects (for each 5 years of
age) with different primary enucleation indications is
shown in Figure 1. Retinoblastoma was the most common
primary enucleation indication in 0- to 5-year-old patients.
Frequency of enucleations due to uveal melanoma increased
from the 31 years of age in our sample (Figure 1).
In the trauma group, the number of male patients was
significantly higher than the number of female patients
(n� 62/30, p< 0.0001); moreover, in the infection/
inflammation group, the number of female subjects was
significantly higher than the number of male subjects
(n� 18/45, p � 0.0007). *ere was no sex predominance in
the systemic disease group (n� 9/19, p � 0.0731), tumour
group (n� 127/132, p � 0.8570), or surgical disease group
(n� 44/42, p � 0.6085) (Figure 2). Because of small sample
sizes, the miscellaneous and not classified groups were not
analysed regarding age or gender distribution.
Primary enucleation indications are displayed in Fig-
ures 3 and 4, as well as in Tables 1 and 2. *ese were (in
decreasing order) tumours (n� 259; 47.3%) (intraocular,
periocular, or intraorbital; Table 1), trauma (n� 92; 16.8%),
surgical diseases (n� 86; 15.7%), infection or inflammation
(n� 63; 11.6%), systemic diseases (n� 28; 5.1%, Table 2),
miscellaneous diseases (n� 11; 2.0%), and not classified
(n� 8; 1.5%). *e number of enucleations per year showed a
decreasing trend over the 12-year period (Figure 4).
Excluding eyes which were enucleated due to acute
trauma, histopathologically there were 332 (64.2%) eyes with
retinal detachment, 109 (21.1%) with angle closure, 105
(20.3%) with optic nerve head cupping, 88 (17.0%) with
intraocular inflammatory reaction, 62 (12.0%) with sub-
retinal, suprachoroidal, or vitreous haemorrhage, 52 (10.1%)
with anterior chamber or pupillary membrane, 38 (7.4%)
with intraocular ossification, and 21 (4.1%) with iris
rubeosis.
In the tumour group, there was RB in 36 (13.9%) and
malignant melanoma (MM) in 200 (77.2%) globes.
*ere were 29 (85.3%) undifferentiated and 5 (14.7%)
differentiated RBs, and there were no histopathological data
for 2 cases (incomplete documentation for this retrospective
study). RBs involved the retinal pigment epithelium (n� 19,
55.9%), choroid (n� 16, 47.1%), vitreous body (n� 14,
41.2%), optic nerve head and optic nerve (with tumour-free
margin in all cases) (n� 10, 29.4%), trabecular meshwork
(n� 7, 20.6%), anterior or posterior chamber (n� 7, 20.6%),
sclera (n� 1, 2.9%) and scleral canal (n� 1, 2.9%), or the
orbit through the sclera (n� 1, 2.9%) and the orbit through
the scleral canal (n� 1, 2.9%).
Choroidal MM was found in 163 (81.5%), ciliary
body MM in 34 (17.0%), and iris MM in 3 (1.5%) eyes.
Histopathologically, 108 (55.7%) were spindle-cell type,
32 (16.5%) were epithelioid-cell type, and 54 (27.8%) were
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mixed-cell-type MMs; there were no histopathological data
available in 6 cases. Local tumour invasion was detected as
follows: into scleral layers in 90 (46.4%), into the retina in 54
(27.8%), into the scleral canal in 19 (9.8%), into scleral
emissary veins in 11 (5.7%), into the anterior chamber angle
in 10 (5.2%), into the trabecular meshwork in 7 (3.6%), into
Schlemm’s canal in 6 (3.1%), and into the optic nerve (but
with tumour-free margin in all cases) in 10 (5.2%) MM
globes. Moreover, local invasion into the orbit was detected
as follows: through scleral layers in 14 (7.2%), through the
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Figure 3: Percentages of primary enucleation indications between
January 2006 and December 2017 at the Department of Oph-
thalmology of Semmelweis University (Budapest, Hungary).
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Figure 1: Age distribution of patients (each 5 years of age) at the
time of enucleation with the primary enucleation indication of
retinoblastoma, uveal melanoma, and other diseases, between
January 2006 and December 2017 at the Department of Oph-
thalmology of Semmelweis University (Budapest, Hungary) (547
eyes of 543 patients).
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Figure 2: Sex distribution of patients who underwent enucleation
(547 eyes of 543 patients) between January 2006 and December
2017 at the Department of Ophthalmology of Semmelweis Uni-
versity (Budapest, Hungary), distributed among primary enucle-
ation indications. *e numbers of patients in different groups were
259 for tumours, 92 for trauma, 86 for surgical diseases, 63 for
infection or inflammation, 28 for systemic, 11 for miscellaneous
diseases, and 8 not classified.
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Figure 4: Primary enucleation indications between January 2006
and December 2017 at the Department of Ophthalmology of
Semmelweis University (Budapest, Hungary).
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scleral canal in 7, (3.6%) and through scleral emissary veins
in 4 (2.1%) eyes.
Other intraocular and periocular and intraorbital tu-
mours (16; 6.2%) leading to enucleation are summarized in
Table 1. Primary tumours in metastatic tumours of the uvea
were lung adenocarcinoma (n� 2; 0.8%) and clear cell
kidney carcinoma (n� 1; 0.4%).
Seven eyes (2.7%) were enucleated with clinical mis-
diagnosis of tumour. *ree globes were enucleated with
suspected RBs; among them, one had persistent hyperplastic
primary vitreous (PHPV), one had Coats’ disease, and one
had retinal detachment due to incontinentia pigmenti, as
their histological diagnoses. Four globes (1.5%) were enu-
cleated with suspected uveal MM; among them, one (0.4%)
had suprachoroidal haemorrhage, one (0.4%) had subretinal
bleeding, one (0.4%) had old retinal detachment, and one
(0.4%) had reactive gliosis of the retina, as their histological
diagnoses.
In the trauma group, the primary location of the wound
or injury was the cornea in 32 eyes (34.8%), corneoscleral
tissue in 24 eyes (26.1%), sclera in 17 eyes (18.5%), at the
optic nerve in 4 eyes (4.3%), and at the lens in 1 eye (1.1%)
(blunt trauma). *e place where the injury occurred was at
home in 50 cases (54.3%), unknown in 18 (19.6%), in traffic
in 8 (8.7%), at work in 7 (7.6%), in a violent act in 7 (7.6%),
and in a sport accident in 2 (2.2%).
In the surgical disease group, 36 (41.9%) patients had
glaucoma, 25 (29.1%) had retinal disease, 19 (22.1%) had
lens-related disease, and 6 (7.0%) had corneal disease.
In the infection/inflammation group, 49 (77.8%) subjects
had keratitis, 5 (7.9%) had chronic uveitis, 3 (4.8%) had
iridocyclitis, 3 (4.8%) had chorioretinitis, 2 (3.2%) had
scleritis, and 1 (1.6%) had endogenous endophthalmitis.
Systemic diseases that were enucleation indications are
shown in Table 2.
In the miscellaneous diseases group, 5 (45.4%) patients
had anterior staphyloma, 2 (18.2%) had persistent hyper-
plastic primary vitreous (PHPV), 1 (9.1%) had myopia, 1
(9.1%) had Rieger syndrome, 1 (9.1%) had facial nerve palsy,
and 1 (9.1%) had microphthalmia.
Immediate clinical enucleation indications were (in de-
creasing order) tumours (n� 252, 46.1%), atrophia or
phthisis bulbi (n� 101, 18.5%), infection or inflammation
(n� 101, 18.5%), painful blind eye due to glaucoma (n� 61,
11.2%), acute trauma (n� 20, 3.7%), threatening or spon-
taneous perforation (n� 7, 1.3%), cosmetological reasons
(n� 3, 0.5%), and expulsive bleeding (n� 2, 0.4%).
Among the 547 enucleated patients, 137 (25.0%) re-
ceived a primary orbital implant at the time of eye removal.
Types of implants were hydroxyapatite in 92 cases (67.2%),
aluminium-oxide ceramic in 23 (16.8%), dermis-fat graft in
20 (14.6%), and silicone in 2 (1.5%).
4. Discussion
To our knowledge, this is the first study regarding ocular
enucleations in Hungary and the first comprehensive study
in Europe in the last 20 years. Enucleation is regarded as the
last resort for many hopeless eye diseases, in which no other
eye-preserving therapy is available; these include untreatable
ocular malignancies, infections, inflammations, or painful
blind eye. Due to differences in methodologies and defini-
tions, comparisons between studies and results are not easy.
Regarding primary indications, patients with trauma
were the youngest (48.6 years) and subjects with inflam-
matory or infectious diseases were the oldest (64.7 years)
among enucleated persons. de Gottrau et al. [3] reported
higher mean age (66.1 years) for surgical diseases, compared
to our study (50.1 years); however, his mean ages for trauma
(44.2 years) and inflammatory or infectious disease
(67.6 years) groups were similar to those of our study (48.6
and 64.7 years).
*e peak incidence of enucleation in Hungary (between
0–5 and 51–85 years) occurred in a similar age group among
pediatric patients to that reported in China (between 0–10
and 31–40 years) [4] or in India (between 0 and 10 years)
[6, 7] and in a similar age group among adult patients to that
Table 1: Primary enucleation indications of enucleated eyes
(n� 259), in decreasing order, with suspected clinical diagnosis of
tumour (uveal melanoma, retinoblastoma, other tumours, and false
clinical suspicion of intraocular tumour) and histopathological
diagnosis of the removed eyes with “other tumours.”
Primary enucleation indications n %
Uveal melanoma 200 77.2
Retinoblastoma 36 13.9
Other tumours 16 6.2
Basal-cell carcinoma 4 1.5
Ocular metastasis 3 1.2
Optic nerve glioma 2 0.8
Orbital adenoid cystic carcinoma 2 0.8
Ocular surface squamous neoplasia 2 0.8
Ocular lymphoma 1 0.4
Ocular multiple myeloma 1 0.4
Choroidal cavernous haemangioma 1 0.4
False clinical suspicion of intraocular tumour 7 2.7
Total 259 100
Table 2: Subspecification of systemic diseases as primary enu-
cleation indication (n� 26), between January 2006 and December
2017, at the Department of Ophthalmology of Semmelweis Uni-
versity, Budapest, Hungary.
Clinicopathological diagnosis n %
Proliferative diabetic retinopathy 5 17.9
Rheumatoid arthritis 4 14.3
Retinal vein occlusion 4 14.3
Lyell’s disease 3 10.7
Ocular ischaemic syndrome 2 7.1
Ocular cicatricial pemphigoid 2 7.1
Sjo¨gren syndrome 2 7.1
Retinal artery occlusion 1 3.6
Sarcoidosis 1 3.6
Coats disease 1 3.6
Wegener’s disease 1 3.6
von Hippel–Lindau disease 1 3.6
Marfan syndrome 1 3.6
Total 28 100
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reported in Germany (between 61 and 75 years) [3]. In
Hungary, in more than 82% of cases, enucleations were
performed in subjects older than 30 years, while in India [6, 7]
and Turkey [8], 82–84% and 54% of enucleations, re-
spectively, were performed in subjects below 30 years of age.
In contrast to previous studies [6,7,9], our data showed a
slight predominance of females undergoing enucleation,
compared to males (51.4% vs. 48.6%). Trauma as a primary
enucleation indication was more common among male than
female patients (67.4% vs. 32.6%), similar to the findings of
de Gottrau et al. (79% vs. 21%) [3], Freitag (75% vs. 25%)
[10], and Cheng (81.3% vs. 18.7%) [4]. Furthermore, similar
to de Gottrau et al. (62.5% vs. 37.5%) [3], ocular infections/
inflammation (71.4% vs. 28.6%) were more common in
females than in males.
In the present study, the most common primary enu-
cleation indications were tumours (47.3%), trauma (16.8%),
surgical diseases (15.7%) and infectious/inflammatory dis-
eases (11.6%). In our study, there is an interesting inversion
in the distribution of eyes with trauma and tumours,
compared to previous studies. Previously, trauma was re-
portedly the most common primary enucleation indication
(62.5% between 2003 and 2006 in China [4]; 37.4% between
1980 and 1990 in Germany [3]; 36.0% between 1982 and
2002 in Poland [11]), and tumours were the second most
common indication (28.5% in China [4]; 20.7% in Poland
[11]; 19.6% in Germany [3]). However, trauma is still
considered the primary cause of enucleation in some de-
veloping countries [5]. *is changing trend is well known
[2, 9, 11–14], due to the improved management of eye
traumas and better surgical tools, which help to prevent eye
loss after severe ocular injuries. *erefore, trauma is not the
most common indication for enucleation in developed
countries anymore.
Furthermore, the number of enucleations with tumours
did not decrease over time in the literature [9, 12]; a similar
result was observed in our series (Figure 4) [15,16]. Similar
to the findings of our study, tumours were also reported as
the leading causes of enucleation in France [17], Turkey [8],
and India [7] in 1996, 1997, and 2018, respectively.
In our study, the most common tumours were uveal MM
among adults and RB in children, similar to the reports from
China [4], Denmark [13], Germany [3], Iceland [9], Iran
[18], and India [7]. *e ratio of RB to MM was 1 : 5.5, which
is similar to previous findings in our geographical region
(France: 1 : 2 [17]; Poland: 1 :13 [11]); notably, it contrasts
with the ratios reported in Asia (China: 1.43 :1 [4]; India:
7.3 :1 [7]). It has been suggested that closer to Equator, MM
has a lower prevalence, whereas RB has a higher prevalence
[4]. Moreover, RB treatment methods are hardly available in
developing countries [19].
In contrast to the results of studies from Western
countries and similar to the findings from China [4], lung
cancer was the most common primary tumour with ocular
metastasis in enucleated globes. *is is consistent with the
fact that lung cancer is a leading cause of death in our
country [20] because smoking is a serious public health
problem in Hungary, compared to its frequency in other
developed countries [21].
Clinical RB misdiagnosis (0.56%) was similar to the rate
reported in China (0.48%) [4] and lower than that reported
in India (6.0%) [6]. Clinical MM misdiagnosis (0.74%) was
lower than the rate reported by de Gottrau et al. (2.3%) [3]
and Cheng (4.0%) [4]. Additionally, no MMs were clinically
misdiagnosed.
Sigurdsson et al. [9] found that work accidents were
more common than those happening at home (34.7% vs.
26.4%). In contrast, we observed that home accidents
(54.3%) were more common than work accidents (7.6%).
*e location of the primary wound in our series was similar
to that reported by Cheng (mostly corneal/corneoscleral)
[4], although strictly corneal injuries were slightly more
common than corneoscleral wounds in our survey.
Systemic diseases were more common enucleation in-
dications in the report by de Gottreau (17.1%) [3], than in
our study (5.1%). Currently, through introduction of im-
proved conservative and surgical treatment methods, we
may prevent the most serious eye complications of systemic
diseases. Diabetes mellitus (DM) is one of the most common
causes of blindness and severe visual impairment in middle-
aged people. *e most dangerous and common complica-
tions of DM leading to enucleation are proliferative diabetic
retinopathy and retinal vein occlusion [22, 23]. Enucleation
due to systemic diseases has decreased remarkably in recent
decades [12]. *e proportions of retinal vein occlusion and
diabetic retinopathy, as systemic disease causes of enucle-
ation, were 57.7% and 32.7% in the study by de Gottrau et al.
[3], whereas they were 14.3% and 17.9% in our study. Ex-
planations are readily available: regular control and well-
organized screening for DM, modern antidiabetic agents,
introduction of panretinal photocoagulation, and vitreor-
etinal surgery can prevent and treat severe eye complications
of DM [13].
Similar to the findings in the study by Cheng (5.3%) [4],
we found iris rubeosis in 4.1% of the globes. *is value is
remarkably lower than that reported by de Gottrau et al.
(48.0%) [3] and seems to refute the concept that most
secondary angle closures follow rubeosis iridis [24].
*e order of other primary enucleation indications in
our study was similar to earlier reports. Tumour, trauma,
and systemic diseases were followed by surgical (15.7% vs.
5.7–14.1%) and inflammatory/infectious diseases (11.6% vs.
1.7–7.0%) [3, 4]. Despite the development of microsurgical
instruments and modern antibiotics, the frequency of
surgical-related enucleations has not changed over time [3].
Anterior staphyloma (1.0%) was a rare primary enucleation
indication, in contrast to the rate reported by Vemuganti
from India [6] (49.0%), where anterior staphyloma was the
most common primary cause of enucleation. Reportedly,
anterior staphyloma is a rarity in Western countries but is a
common condition in Asia [25].
*e main clinical immediate indications for enucleation
were tumours (46.1%), followed by atrophy or phthisis bulbi
(18.5%) (similar to the new reports from India [7]), infection
or inflammation (18.5%), painful blind eye secondary to
glaucoma (11.2%), and acute trauma (3.7%). In China [4],
64.9% of all enucleations were performed in patients with
atrophia or phthisis bulbi (36.4%) and tumours (28.5%),
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which is almost the same as our 64.6%, but in the reverse
order. de Gottrau et al. [3] also reported similar results with
one exception, almost 25 years ago. In his study, secondary
glaucoma was the most common (34.9%) clinical indication
for enucleation, whereas tumours were the second most
common indication (21.7%). Most studies reported nearly
similar proportions for glaucoma in enucleated eyes (USA:
8.0% [12]; China: 10.1% [4]; Denmark: 15.0% [13]; Turkey:
16.0% [8]; France: 16.0% [17]) to those found in our present
work (11.2%). Worldwide, enucleation due to glaucoma has
shown a decreasing trend over multiple decades. Setlur et al.
found that, from the 1960s to the 2000s, there was a de-
creasing tendency, from 31% to 8.4% [12, 26]. *e main
explanation for this decrease may be introduction of modern
therapeutic (antiglaucoma and antidiabetic agents) and
surgical methods, which help to rescue many glaucomatous
eyes and prevent serious eye complications [9, 13].
After excluding globes with tumour and acute trau-
ma—similar to the method used by Cheng [4]—retinal
detachment was most frequently associated with atrophia or
phthisis bulbi (71.0%) in our series.
Approximately every fourth patient received an orbital
implant following enucleation. *e reason for this low
proportion is that, in Hungary, financing of orbital implants
is generally not covered by health insurance, nor is it in-
cluded in the surgical costs of enucleation. Other studies
have reported much higher rates of orbital implants (92–
100%) [5, 27]. In the literature, hydroxyapatite implants
were most frequently used (67.2%) [5, 18, 28].
5. Conclusions
In summary, intraocular tumours represent the most
common clinicopathological indication for ocular enucle-
ation in our study population. Following ocular trauma and
systemic diseases, the rate of enucleation decreased in the
last decade, compared to those previously reported in other
developed countries. However, changes were not observed
for surgical diseases, infectious and inflammatory causes, or
miscellaneous and unclassified diseases. Orbital implant
financing in Hungary should be increased to achieve better
postoperative aesthetic rehabilitation following enucleation.
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